Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.

Garnett S, Dutchak KL, McDonough RV, Dankort D.

Oncogene. 2017 Nov 9;36(45):6325-6335. doi: 10.1038/onc.2017.235. Epub 2017 Jul 24.

PMID:
28745322
2.

Construction of Modular Lentiviral Vectors for Effective Gene Expression and Knockdown.

de Bruyns A, Geiling B, Dankort D.

Methods Mol Biol. 2016;1448:3-21. doi: 10.1007/978-1-4939-3753-0_1.

PMID:
27317169
3.

TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Shai A, Dankort D, Juan J, Green S, McMahon M.

Cancer Res. 2015 Aug 1;75(15):3167-80. doi: 10.1158/0008-5472.CAN-14-3701. Epub 2015 May 22.

4.

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M.

Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014.

5.

The inhibitor of kappa B kinase-epsilon regulates MMP-3 expression levels and can promote lung metastasis.

Seccareccia E, Pinard M, Wang N, Li S, Burnier J, Dankort D, Brodt P.

Oncogenesis. 2014 Aug 18;3:e116. doi: 10.1038/oncsis.2014.28.

6.

RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Ramdzan ZM, Vadnais C, Pal R, Vandal G, Cadieux C, Leduy L, Davoudi S, Hulea L, Yao L, Karnezis AN, Paquet M, Dankort D, Nepveu A.

PLoS Biol. 2014 Mar 11;12(3):e1001807. doi: 10.1371/journal.pbio.1001807. eCollection 2014 Mar.

7.

Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.

Vandal G, Geiling B, Dankort D.

PLoS One. 2014 Jan 28;9(1):e84745. doi: 10.1371/journal.pone.0084745. eCollection 2014.

8.

Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.

Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD.

Mol Cancer Res. 2013 Dec;11(12):1530-41. doi: 10.1158/1541-7786.MCR-13-0294. Epub 2013 Oct 23.

9.

A modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivo.

Geiling B, Vandal G, Posner AR, de Bruyns A, Dutchak KL, Garnett S, Dankort D.

PLoS One. 2013 Oct 11;8(10):e76279. doi: 10.1371/journal.pone.0076279. eCollection 2013.

10.

Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma.

Mito JK, Min HD, Ma Y, Carter JE, Brigman BE, Dodd L, Dankort D, McMahon M, Kirsch DG.

J Pathol. 2013 Jan;229(1):132-40. doi: 10.1002/path.4099. Epub 2012 Nov 20.

11.

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.

Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 15;72(18):4765-76. Epub 2012 Jul 25.

12.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93. Epub 2012 May 24.

13.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

14.

β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M.

Cancer Cell. 2011 Dec 13;20(6):741-54. doi: 10.1016/j.ccr.2011.10.030.

15.

Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents.

Revet I, Feeney L, Bruguera S, Wilson W, Dong TK, Oh DH, Dankort D, Cleaver JE.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8663-7. doi: 10.1073/pnas.1105866108. Epub 2011 May 9.

16.

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.

Charles RP, Iezza G, Amendola E, Dankort D, McMahon M.

Cancer Res. 2011 Jun 1;71(11):3863-71. doi: 10.1158/0008-5472.CAN-10-4463. Epub 2011 Apr 21.

17.

Characterization of melanoma cells capable of propagating tumors from a single cell.

Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW.

Cancer Res. 2010 Jan 1;70(1):388-97. doi: 10.1158/0008-5472.CAN-09-2153.

18.

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M.

Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12.

19.

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M.

Genes Dev. 2007 Feb 15;21(4):379-84. Epub 2007 Feb 13.

20.

The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation.

Kim H, Chan R, Dankort DL, Zuo D, Najoukas M, Park M, Muller WJ.

Oncogene. 2005 Nov 17;24(51):7599-607.

PMID:
16170374
21.

ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter.

Loureiro RM, Maharaj AS, Dankort D, Muller WJ, D'Amore PA.

Biochem Biophys Res Commun. 2005 Jan 14;326(2):455-65.

PMID:
15582599
22.

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Khoury H, Naujokas MA, Zuo D, Sangwan V, Frigault MM, Petkiewicz S, Dankort DL, Muller WJ, Park M.

Mol Biol Cell. 2005 Feb;16(2):550-61. Epub 2004 Nov 17.

23.

Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development.

Chan R, Hardy WR, Dankort D, Laing MA, Muller WJ.

Development. 2004 Nov;131(22):5551-60. Epub 2004 Oct 20.

24.

Memo mediates ErbB2-driven cell motility.

Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A.

Nat Cell Biol. 2004 Jun;6(6):515-22. Epub 2004 May 23.

PMID:
15156151
25.

The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.

Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, Holash J, Yancopoulos GD, Muller WJ, Pawson T, Park M.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2345-50.

26.

Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model.

Settle M, Gordon MD, Nadella M, Dankort D, Muller W, Jacobs JR.

Oncogene. 2003 Apr 3;22(13):1916-26.

PMID:
12673197
27.

Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.

Dankort D, Jeyabalan N, Jones N, Dumont DJ, Muller WJ.

J Biol Chem. 2001 Oct 19;276(42):38921-8. Epub 2001 Aug 10.

28.

Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor.

Khoury H, Dankort DL, Sadekova S, Naujokas MA, Muller WJ, Park M.

Oncogene. 2001 Feb 15;20(7):788-99.

29.

Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.

Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, Muller WJ.

Mol Cell Biol. 2001 Mar;21(5):1540-51.

30.

Oncogene mediated signal transduction in transgenic mouse models of human breast cancer.

Siegel PM, Dankort DL, Muller WJ.

Adv Exp Med Biol. 2000;480:185-94. Review. No abstract available.

PMID:
10959426
31.

Signal transduction in mammary tumorigenesis: a transgenic perspective.

Dankort DL, Muller WJ.

Oncogene. 2000 Feb 21;19(8):1038-44. Review.

PMID:
10713687
32.

Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ.

Mol Cell Biol. 1997 Sep;17(9):5410-25.

33.

Transgenic models of breast cancer metastasis.

Dankort DL, Muller WJ.

Cancer Treat Res. 1996;83:71-88. Review. No abstract available.

PMID:
8826642
34.

Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Siegel PM, Dankort DL, Hardy WR, Muller WJ.

Mol Cell Biol. 1994 Nov;14(11):7068-77.

35.

Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.

Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ.

Mol Cell Biol. 1994 Jan;14(1):735-43.

36.

Isolation of chicken phosphotyrosyl phosphatase cDNA sequences and identification of a brain-specific species related to human PTP zeta.

Rowley RB, Lee JM, Corbeil HB, Charbonneau R, Jue K, Dankort DL, Branton PE.

Cell Mol Biol Res. 1993;39(3):209-19.

PMID:
8293038

Supplemental Content

Loading ...
Support Center